Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide
Arthritis Care & Research · 2024-02 · 76 (2) · 288-294
DOI: 10.1002/acr.25222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 28.10.2023. Verfasst von Elizabeth Nettleton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, Wisconsin. Hauptthemen laut MEDLINE: Pneumocystis carinii, Pneumonia, Pneumocystis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation.
Abstract (Originalsprache)
Objective
This manuscript assesses the incidence of Pneumocystis jiroveci pneumonia (PJP) among patients receiving contemporary treatment regimens for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and adverse events associated with PJP prophylaxis.
Methods
Incident users of rituximab or cyclophosphamide for AAV were identified in the TriNetX electronic health records database from 2011 to 2022. The incidence rates (IRs) of PJP in the first 6 months of induction therapy with rituximab and/or cyclophosphamide and during postinduction maintenance therapy with rituximab were calculated. Cox proportional hazard models were used to estimate hazard ratios (HRs) and confidence intervals (CIs) for the risk of adverse events commonly associated with PJP prophylaxis.
Results
We identified 1,461 AAV cases who received induction therapy with rituximab (69.7%), cyclophosphamide (18.9%), or both (11.4%). Prophylaxis prescribed within 30 days of induction included trimethoprim‐sulfamethoxazole (30.7%), atovaquone (5.4%), dapsone (3.8%), and pentamidine (0.8%). During induction therapy, 10 cases of PJP were identified (IR 15.0 cases per 1,000 patient‐years); no deaths occurred. In adjusted analyses, those who received prophylaxis had a higher risk of leukopenia (HR 3.1; 95% CI 1.1–8.6), rash (HR 1.9; 95% CI 1.0–3.6), and nephropathy (HR 2.6; 95% CI 1.3–5.1) than those who did not. During rituximab maintenance therapy (n = 709), five cases of PJP were identified (IR 2.1 cases per 1,000 person‐years), one of whom died during the hospitalization associated with a PJP diagnosis.
Conclusion
Rates of PJP in patients with AAV were lower than previously observed, and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical College of Wisconsin, Milwaukee, Wisconsin.
- University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Elizabeth Nettleton, Sebastian E Sattui
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Rheumatology Research Foundation
Zitieren
APA
Nettleton, E., Sattui, S. E., Wallace, Z., & Putman, M. (2024). Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care & Research, 76(2), 288-294. https://doi.org/10.1002/acr.25222
Vancouver
Nettleton E, Sattui SE, Wallace Z, Putman M. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care & Research. 2024;76(2):288-294. doi:10.1002/acr.25222
BibTeX
@article{Nettleton2024,
author = {Nettleton, Elizabeth and Sattui, Sebastian E and Wallace, Zachary and Putman, Michael},
title = {Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide},
journal = {Arthritis Care & Research},
year = {2024},
volume = {76},
number = {2},
pages = {288--294},
doi = {10.1002/acr.25222}
}
EUVIMED